Papers: 22 Aug 2014 - 29 Aug 2014

This visualization demonstrates a mystery related to relapsing remitting multiple sclerosis (RRMS). For some unknown reason, the annualized relapse rates (ARRs) among RRMS patients in the placebo arms of phase 3 trials have decreased substantially over the last two decades. In the 1990s ARRs tended to be above 1.0, but more recently ARRs have been 0.5 and below.